Your Cart is Empty
Start shopping
EYLEA®
EYLEA® (English Alternative)
Note: Actual packaging may vary.
EYLEA® (English Alternative)
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 - 3 | — | $1,599.00 |
| 4 - 10 | 6.25 % | $1,499.00 |
| 11 - 20 | 6.88 % | $1,489.00 |
| 21+ | 7.5 % | $1,479.00 |
Eylea® is indicated for adults for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD)
- Visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO)
- Visual impairment due to diabetic macular edema (DME)
- Visual impairment due to myopic choroidal neo-vascularization (myopic CNV)
EYLEA® is indicated in preterm infants for the treatment of:
- Retinopathy of pre-maturity (ROP) with zone I (stage 1+, 2+, 3, or 3+), zone II (stage 2+ or 3+), or AP-ROP (aggressive posterior ROP) disease.
EYLEA® is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Retinopathy of Pre-maturity (ROP)
Eylea® is a 40 mg/mL solution for injection in a pre-filled syringe. One mL solution contains 40 mg aflibercept. One pre-filled syringe contains an extractable volume of at least 0.09 mL, equivalent to at least 3.6 mg aflibercept.
Preparation: The patient is seated comfortably in privacy…
Anesthesia: An anesthetic injection may also be given near the eye…
Speculum Insertion: A device called a lid speculum may be used to keep the eyelids open…
Injection: The healthcare provider will then inject the Eylea® solution into the vitreous humor…
Aftercare: Following the procedure, the patient will need to have their eye monitored for potential side effects including those affecting vision…
Contraindications
- Ocular or Periocular Infections: EYLEA® is contraindicated in patients with ocular or periocular infections.
- Active Intra-ocular Inflammation: EYLEA® is contraindicated in patients with active intra-ocular inflammation.
- Hypersensitivity: EYLEA® is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in EYLEA®…
After-care
In the days following EYLEA® administration, patients are at risk of developing endophthalmitis, retinal detachment, or retinal vasculitis with or without occlusion…
Acute increases in intra-ocular pressure have been seen within 60 minutes of intra-vitreal injection, including with EYLEA®…
Patients may experience temporary visual disturbances after an intra-vitreal injection with EYLEA®…
Advise patients not to drive or use machinery until visual function has recovered sufficiently.
Eylea® is indicated for adults for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD)
- Visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO)
- Visual impairment due to diabetic macular edema (DME)
- Visual impairment due to myopic choroidal neo-vascularization (myopic CNV)
EYLEA® is indicated in preterm infants for the treatment of:
- Retinopathy of pre-maturity (ROP) with zone I (stage 1+, 2+, 3, or 3+), zone II (stage 2+ or 3+), or AP-ROP (aggressive posterior ROP) disease.
EYLEA® is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Retinopathy of Pre-maturity (ROP)
Eylea® is a 40 mg/mL solution for injection in a pre-filled syringe. One mL solution contains 40 mg aflibercept. One pre-filled syringe contains an extractable volume of at least 0.09 mL, equivalent to at least 3.6 mg aflibercept.
Preparation: The patient is seated comfortably in privacy…
Anesthesia: An anesthetic injection may also be given near the eye…
Speculum Insertion: A device called a lid speculum may be used to keep the eyelids open…
Injection: The healthcare provider will then inject the Eylea® solution into the vitreous humor…
Aftercare: Following the procedure, the patient will need to have their eye monitored for potential side effects including those affecting vision…
Contraindications
- Ocular or Periocular Infections: EYLEA® is contraindicated in patients with ocular or periocular infections.
- Active Intra-ocular Inflammation: EYLEA® is contraindicated in patients with active intra-ocular inflammation.
- Hypersensitivity: EYLEA® is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in EYLEA®…
After-care
In the days following EYLEA® administration, patients are at risk of developing endophthalmitis, retinal detachment, or retinal vasculitis with or without occlusion…
Acute increases in intra-ocular pressure have been seen within 60 minutes of intra-vitreal injection, including with EYLEA®…
Patients may experience temporary visual disturbances after an intra-vitreal injection with EYLEA®…
Advise patients not to drive or use machinery until visual function has recovered sufficiently.
Frequently Bought Together
About the product
Eylea® is a drug used to treat wet age-related macular degeneration. It is also used to treat swelling in the retina caused by a blockage in the blood vessels. Product information is included in each package, for customers who buy Eylea® online